Previous 10 | Next 10 |
2024-06-15 11:19:01 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Teva Pharmaceutical Industries Limited (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Eli Lilly and Company (LLY) Goldman Sac...
2024-06-15 07:28:25 ET More on Novo Nordisk Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Employee benefits survey finds marke...
2024-06-15 06:50:00 ET Have you ever felt anxiety about clicking the final button to buy a stock? Some investors agonize over their decisions. It doesn't have to be that way, though, if you find the right stocks. Three Motley Fool contributors believe they've identified good picks -- an...
2024-06-14 18:24:23 ET More on Eli Lilly, Novartis, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Em...
2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...
2024-06-14 08:01:46 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Road To Approval Of Donanemab Is Open Eli Lilly and Company (LLY) Goldman Sachs 45th Annual Global Healthcare Conference Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? ...
2024-06-14 06:15:00 ET Few industries are more essential than healthcare. That makes it an excellent place to look for stocks that can perform well over extended periods since the basic services they offer are unlikely to become obsolete anytime soon. However, that doesn't guarantee suc...
2024-06-14 05:50:00 ET Novo Nordisk 's (NYSE: NVO) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024. But note the use of the word "currently." Wegovy's market-topping po...
2024-06-13 09:49:40 ET More on JPMorgan Chase JPMorgan Chase & Co. (JPM) Morgan Stanley US Financials, Payments & CRE Conference JPMorgan Chase: Just By Opening 500 New Branches, It Could Potentially Generate Another $9.11B In Revenues JPMorgan Chase hires fo...
2024-06-13 08:58:36 ET More on Vivani Medical Seeking Alpha’s Quant Rating on Vivani Medical Historical earnings data for Vivani Medical Financial information for Vivani Medical Read the full article on Seeking Alpha For further details see: ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...